automated design ligands polypharmacological profiles
clinical efficacy safety drug determined activity profile across many proteins proteome however designing drugs specific multi-target profile complex difficult therefore methods design drugs rationally priori profiles several proteins immense value drug discovery describe new approach automated design ligands profiles multiple drug targets method demonstrated evolution approved acetylcholinesterase inhibitor drug brain-penetrable ligands either specific polypharmacology exquisite selectivity profiles g-protein-coupled receptors overall ligand-target predictions prospectively designed ligands tested experimentally % confirmed correct also demonstrate target engagement vivo approach can useful source drug leads multi-target profiles required achieve either selectivity drug targets desired polypharmacology
